Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow TMO
Thermo Fisher Scientific Inc. (TMO) P/S ratio
As of 16 October 2026, Thermo Fisher Scientific Inc. (TMO) trades at a P/S ratio of 5.5×. Over the past ten years it has ranged from 2.8× (September 2015) to 7.3× (November 2020); the current reading is higher than 88% of that period. That is above the Diagnostics & Research industry median of 4.4× and above the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 4.9× | 5.79% |
| FY2024 | 4.6× | (5.44%) |
| FY2023 | 4.9× | 1.51% |
| FY2022 | 4.8× | (27.99%) |
| FY2021 | 6.7× | 17.11% |
| FY2020 | 5.7× | 12.53% |
| FY2019 | 5.1× | 37.75% |
| FY2018 | 3.7× | 1.35% |
| FY2017 | 3.6× | 17.34% |
| FY2016 | 3.1× | (6.92%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 4.0× | (0.77%) |
| Mar 2026 | 4.0× | (17.49%) |
| Dec 2025 | 4.9× | 16.96% |
| Sep 2025 | 4.2× | 18.19% |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| IQV IQVIA Holdings Inc. compare | 2.6× |
| TMO Thermo Fisher Scientific Inc. | 5.5× |
| DHR Danaher Corporation compare | 6.4× |
| A Agilent Technologies, Inc. compare | 6.6× |
| MTD Mettler-Toledo International, Inc. compare | 7.9× |
| ILMN Illumina, Inc. compare | 8.8× |
| WAT Waters Corporation compare | 9.2× |
| IDXX IDEXX Laboratories, Inc. compare | 9.7× |
| NTRA Natera, Inc. compare | 20.7× |
| Diagnostics & Research industry median | 4.4× |
| Healthcare sector median | 3.4× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on TMO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement